Free shipping on all orders over $ 500

SB1317

Cat. No. M2239

All AbMole products are for research use only, cannot be used for human consumption.

SB1317 Structure
Synonym:

TG02

Size Price Availability Quantity
5mg USD 95  USD95 In stock
10mg USD 140  USD140 In stock
25mg USD 300  USD300 In stock
50mg USD 425  USD425 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SB1317 (TG02) is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. SB1317 dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). In vivo, SB1317 (TG02) exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.

Chemical Information
Molecular Weight 372.46
Formula C23H24N4O
CAS Number 937270-47-8
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yu-Ting Su, et al. Novel Targeting of Transcription and Metabolism in Glioblastoma

[2] Anthony D William, et al. Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors

[3] Anders Poulsen, et al. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

[4] Mohammed Khalid Pasha, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor

[5] Anthony D William, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus k䲧畸Ỵ畹㧀畷羹皖睑ꏰऒŤऒĀ�皘嶁皔Ѐ瑖徿䀹ࣵ

Related CDK Products
(E/Z)-Zotiraciclib citrate

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor.

Abemaciclib metabolites M2

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively.

CDK9-IN-1

CDK9-IN-1 is a novel, selective CDK9 inhibitor, with an IC50 of 39 nM for CDK9/CycT1, it can be used for the research of HIV infection.

XO44

XO44 (PF-6808472) is a broad-spectrum covalent kinase probe.

ML 315 

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: SB1317, TG02 supplier, CDK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.